GENELABS ANNOUNCES ISSUANCE OF U.S. PATENT ON DHEA COMPOSITION AND METHOD

Genelabs Technologies, Inc. announced today the issuance of U.S. patent No. 7,045,513 entitled "DHEA Composition and Method." The patent claims pharmaceutical formulations of dehydroepiandrosterone, or DHEA, in certain purified polymorphic forms. DHEA is the active ingredient in Prestara, the company's investigational drug for systemic lupus erythematosus, or lupus.
Yahoo News